Skip to main content

Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment

Crispr Therapeutics and Vertex Pharmaceuticals got U.S. regulatory approval for a sickle-cell disease treatment based on the gene-editing technology Crispr.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.